Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
Pfizer reported first-quarter 2026 revenue of $14.5 billion, up 5% year-over-year (2% operationally), driven by a 22% operational surge in launched and acquired products like Padcev and Eliquis. The company reaffirmed full-year 2026 guidance for revenues of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, supported by $2.5 billion in R&D investment and positive Phase 3 readouts across its oncology and rare disease pipelines.
Key figures
- Eps
- 0.75
- Revenue
- $14.5 billion
- Guidance
- Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00
- Revenue Yoy
- 5%
- Reported eps
- 0.47
- Rd investment
- $2.5 billion
- Dividend total
- $2.4 billion
- Dividend per share
- $0.43
- Remaining buyback auth
- $3.3 billion
- Launched products op growth
- 22%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.